The aim of this study was to assess the efficacy of lornoxicam (LNX) in the treatment of acute migraine attacks. Material and Methods: This prospective, randomized, double-blind, placebo-controlled trial was conducted administering either LNX or placebo to patients who were diagnosed with migraine without aura according to the International Headache Society (the year 2004) criteria between 2010 and 2012 Results: Of 44 patients with 120 migraine attacks, 38 were female and rest were males. Mean age was 37.75 ± 9.28 years. Patients recorded using LNX in 87 migraine attacks and placebo in 33 migraine attacks, respectively. Pain intensity scores of the patients were found similar between LNX and placebo groups, statistically. Conclusion: Although oral LNX was found to have efficacy similar to placebo statistically in the treatment of acute migraine attacks, further studies are needed to evaluate appropriately the efficacy of LNX for treatment of acute migraine attacks.
Cabalar, Murat Cabalar; Dincer, Selcuk; and Ozyalcin, Suleyman
"Is oral lornoxicam effective in the treatment of acute migraine attacks? : a randomized-controlled study,"
Pakistan Journal of Neurological Sciences (PJNS): Vol. 10
, Article 10.
Available at: http://ecommons.aku.edu/pjns/vol10/iss3/10